Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically documented AML, ALL, MDS, CML, Acute myeloid leukemia (AML) with one or more of the following criteria~  * CR 1 with poor risk features~ * CR 2, or higher order CR~* Acute lymphoblastic leukemia (ALL) with one of the following criteria~  * CR 1 with poor risk features~ * CR 2, or higher order CR~* Myelodysplasia, RAEB I~* Donor has been identified~* Age ≤ 65 years.~* Performance Status 0-1.~Exclusion Criteria:~* Patients relapsing \<6 months after autologous SCT are not eligible.~* Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection.~* Non-pregnant and non-nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Total body Irradiation; Thiotepa; Fludarabine; Rabbit ATG;
- 2 (Type: EXPERIMENTAL): Palifermin; Total Body Irradiation; Thiotepa; Fludarabine; Rabbit ATG

Based on this trial design, predict the completion outcome and termination type (if applicable).